![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
![[up]](/style/images/multi_up.png)
Up a level- NLM Classification (6)
- WK Endocrine system (4)
- WK 500-590 Pituitary gland (4)
- WK Endocrine system (4)
Number of items at this level: 4.
Adlbrecht, C. and Wild, C. (2010): Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors. Decision Support Document 40.
Adlbrecht, C. and Wild, C. (2007): [Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors. HTA in hospitals]. Decision Support Document 02.
Wild, C. (2003): [Recombinant human growth hormone (GH) therapy]. HTA-Newsletter 21: p. 2.
Wild, C. and Adlbrecht, C. (2007): [Radiopharmaceuticals in palliative care]. HTA-Newsletter 58: pp. 2-3.